CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Survival Outcomes, Adverse Events and Predictive Biomarkers for CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer, an Ambispective Single-center Cohort Study

This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.

Inclusion Criteria:

• Aged ≥18 and older
• Confirmed diagnosis of hormone receptor-positive breast cancer.
• Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy.
• Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease.
• ECOG 0-2
• Adequate organ function

Exclusion Criteria:

• Subjects disable to swallow pills.
• History of immunodeficiency disease